Neuland Laboratories Limited reported robust growth for the fiscal year ended March 31, 2026, with total revenue reaching ₹2,05,315.16 lakhs. The company has recommended a final dividend of ₹34 per share. Additionally, the Board has approved a capacity enhancement at Unit 1 in Telangana with an investment of ₹143.4 crores to meet growing customer demand, while also welcoming Dr. Mauricio Futran as an Additional Director.
Fiscal Year 2026 Financial Highlights
Neuland Laboratories delivered strong financial performance for the year ended March 31, 2026. The company recorded a total income of ₹2,05,315.16 lakhs, marking a significant increase from the previous year. Net profit for the period reached ₹36,399.84 lakhs. For the final quarter (Q4) of FY26, the company reported revenue of ₹77,625.03 lakhs, with a profit of ₹21,267.26 lakhs.
Strategic Dividend and Leadership
The Board of Directors has recommended a final dividend of ₹34/- per equity share (340%) on a face value of ₹10/- for the financial year 2025-26. The dividend is subject to approval by shareholders at the 42nd Annual General Meeting scheduled for August 4, 2026. Furthermore, the company has strengthened its leadership team with the appointment of Dr. Mauricio Futran as an Additional Director, effective May 12, 2026.
Capacity Expansion at Unit 1
To capitalize on growing market demand, Neuland Laboratories is expanding the capacity of its Unit 1 facility located in Bonthapally Village, Telangana. The project involves a proposed capacity addition of 120.5 KL, supplementing the existing 256 KL capacity. The company plans to invest ₹143.4 crores (inclusive of GST) in this expansion, which is expected to be completed within 12 to 18 months. The project will be financed through a combination of internal accruals and borrowings.
Source: BSE
